The Provisions for Medical Device Registration and Filing (SAMR Decree No. 47) is the departmental rule that turns the principles of China’s medical device regulation into an actual submission process. Issued on 26 August 2021 and effective from 1 October 2021, it is the document most often cited — and most often quoted out of context — in English-language registration guides. This article reads it from the perspective of an overseas manufacturer: what the rule actually says, which provisions change your project plan, and where case-specific confirmation is needed.
1. Where Decree No. 47 sits in the framework
The rule was formulated in accordance with the Regulations on the Supervision and Administration of Medical Devices (State Council Decree No. 739), the administrative regulation effective since 1 June 2021. In short: Decree No. 739 establishes the registrant / filing-holder system and the classification principle; Decree No. 47 sets out how registration and filing are actually carried out. A companion rule, SAMR Decree No. 48, addresses in vitro diagnostic reagents. The NMPA also issued an implementation announcement covering transitional arrangements and the earlier registration documents abolished when the two rules took effect.
2. Registration and filing are two different procedures
Decree No. 47 defines registration as the process in which an applicant submits an application and the drug regulatory department reviews safety, effectiveness and quality controllability before deciding whether to approve it. Filing is different: the filer submits documentation which the authority keeps on record for reference. The distinction is not cosmetic — it determines the dossier, the review activity and the resulting document.
| Class | Procedure | Route for imported devices | Practical note |
|---|---|---|---|
| Class I low risk, routine management sufficient | Filing (备案) | Filed with the NMPA | No clinical evaluation data is required for the Class I filing, per the NMPA implementation announcement. |
| Class II moderate risk, strict control required | Registration (注册) | Reviewed by the NMPA; registration certificate issued on approval | Technical evaluation is conducted by the NMPA’s Center for Medical Device Evaluation. |
| Class III higher risk, special measures required | Registration (注册) | Reviewed by the NMPA; registration certificate issued on approval | The highest level of scrutiny; clinical evaluation and quality system evidence are central. |
For domestic products the routes differ: Class I filings go to municipal authorities and domestic Class II registration to provincial authorities. Because an overseas manufacturer exports into China, the national route in the table normally applies. Confirm the class first — see China medical device classification — because a wrong determination sends the entire dossier down the wrong path. The class definitions come from Decree No. 739 and the Rules for Classification of Medical Devices; the catalogue and classification determination documents then fix the class for a specific product.
3. The China legal agent is a regulatory requirement
Decree No. 47 requires applicants and filers to be enterprises or research institutions capable of bearing the corresponding legal responsibility, and requires overseas applicants and filers to appoint an enterprise legal person in China as their agent to handle registration and filing matters. The agent must assist the overseas registrant or filer in fulfilling the obligations set out in the regulation.
This is a regulatory role, not a distribution arrangement. A distributor answers commercial questions; the agent is the entity named in the submission and the channel through which regulatory correspondence, changes and post-market matters are handled. Choosing well at the outset avoids a later change of representation. See China Medical Device Agent services, the explainer on the agent’s duties, and changing your China agent.
4. Dossier language and evidence from your home market
Two provisions regularly surprise teams preparing their first China submission.
4.1 The dossier is in Chinese
Registration and filing materials must be submitted in accordance with NMPA requirements, the applicant is responsible for their truthfulness, and the materials must be in Chinese. Where material has been translated from a foreign language, the original must be provided at the same time. Unpublished literature cited in the dossier requires permission from the rights holder. In practice this means translation quality and source-document control are part of project planning, not a final administrative step.
4.2 Proof of marketing status in the country of origin
For imported device registration and Class I filing, the rule calls for a document issued by the competent authority in the country or region where the applicant is registered or the product is manufactured, evidencing that the device is permitted to be marketed there. The text also addresses cases where the home country does not regulate the product as a medical device, and provides an exception for innovative devices not yet marketed overseas. How these provisions apply to a given product and market is fact-specific and should be confirmed against the current text and applicable guidance before building the dossier.
5. Classification comes before documentation
Decree No. 47 states that registration and filing must follow the classification rules and the classification catalogue. This is why classification is the first real decision in a China project: it determines the procedure, the receiving authority, the dossier depth and whether clinical evaluation evidence is needed. Where a product is new or its class is unclear, the NMPA’s classification definition process exists to resolve the question. Our pages on classification catalogue adjustments and the Class I, Class II and Class III dossier requirements cover the downstream detail.
6. Clinical evaluation is route-dependent
The rule requires clinical evaluation for device registration and filing except in specified circumstances, and provides for an NMPA-published list of devices exempt from clinical evaluation. Depending on the product’s characteristics, clinical risk and available data, evaluation may proceed by analysis of clinical literature and data for a same-variety device, or by clinical trial; where existing evidence is insufficient, a trial is required. The NMPA issues clinical evaluation guidelines. This is a major planning variable, and it is covered in more depth in Clinical evaluation in China. We do not state a standard timeline for any of these routes.
7. Obligations continue after the first approval
The regulation places lifecycle quality management responsibility on the registrant or filer, and the framework covers changes to a registered product, renewal of registration certificates, quality management system verification, adverse event monitoring and recalls. These are continuing duties rather than one-off deliverables. Depending on your product’s stage, see change registration, registration renewal, QMS and GMP compliance and post-market obligations Q&A.
8. A pre-submission checklist for overseas manufacturers
- Confirm the device’s class against the current catalogue and any classification determination documents.
- Decide filing versus registration, and identify the receiving authority for an imported product.
- Appoint a China enterprise legal person as agent and put the regulatory scope in writing.
- Plan the dossier in Chinese, with original-language documents retained alongside translations.
- Establish whether home-market marketing evidence is available and in what form.
- Determine the clinical evaluation route early, including whether an exemption applies.
- Check the dossier against current mandatory standards, product technical requirements, instructions and labelling rules.
- Set up a process for tracking announcements and guidelines between submission and decision.
For the underlying administrative regulation, see Decree No. 739 in brief. For the official texts and their current status, see official regulation sources.
Frequently asked questions
QIs SAMR Decree No. 47 the same as the older Provisions for Medical Device Registration?
No. Decree No. 47 is the 2021 rule that took effect on 1 October 2021. The NMPA implementation announcement issued at the time set out transitional arrangements and stated that a list of earlier registration management documents was abolished when the new rules took effect. Older CFDA-era registration procedures should not be used to plan a current submission.
QDo imported Class I devices need registration?
No. Under Decree No. 47, Class I devices are subject to filing, and imported Class I filings are submitted to the NMPA. Class II and Class III devices require registration, with imported products reviewed by the NMPA. The NMPA implementation announcement also confirms that no clinical evaluation data is submitted for a Class I filing.
QCan our distributor act as our agent?
Decree No. 47 requires overseas applicants and filers to appoint an enterprise legal person in China as agent. Whether an existing commercial partner can take on that regulatory role depends on the entity, the agreement and the responsibilities involved; the roles should be kept distinct in the submission and in post-market arrangements. See our China agent service.
QMust the submission dossier be in Chinese?
Yes. The rule requires registration and filing materials to be in Chinese, and requires the original to be provided alongside material translated from a foreign language. Plan translation and source-document control as part of the dossier build, not as a final step.
QWhat if our device is not marketed in its home country?
The rule addresses both innovative devices not yet marketed overseas and products that the home country does not regulate as medical devices, with specific documentation consequences. Which situation applies depends on the product and the market, and the current official text and NMPA guidance should be checked for the individual case.
QHow long does registration take under Decree No. 47?
The regulation sets timeframes for defined procedural steps, but those are not a project schedule. End-to-end duration depends on classification, testing, clinical evaluation, dossier quality and any supplementary information requested. We deliberately do not quote a general approval timeline, fee or success rate.
Official sources
The following links point to regulator or government-operated sites. Chinese originals are the authoritative texts; English materials are working references. Check the current version before relying on any document in a submission.
- NMPA English — Provisions for Medical Device Registration and Filing (full text) — SAMR Decree No. 47, issued 26 August 2021, effective 1 October 2021.
- SAMR — Provisions for Medical Device Registration and Filing (Chinese original) — Authoritative Chinese text with download options.
- SAMR — official PDF of Decree No. 47 — Direct official PDF download.
- NMPA English — implementation announcement for Decrees No. 47 and No. 48 — Transitional arrangements, imported product filing forms, Class I clinical evaluation data.
- State Council / gov.cn — Regulations on the Supervision and Administration of Medical Devices — State Council Decree No. 739, the parent administrative regulation.
- NMPA English — Rules for Classification of Medical Devices (Decree No. 15) — Official English text of the classification rules.
- NMPA — Notice No. 143 of 2017 on implementing the classification catalogue — How classification documents are applied and which earlier ones remain relevant.
- SAMR laws and regulations database — Verify a text’s current effectiveness status before relying on it.
Working with INTERBRI
INTERBRI works with overseas manufacturers on China medical device registration and filing: confirming the classification and pathway, structuring the Chinese dossier, coordinating testing and clinical evaluation, and providing independent China legal agent representation. Which requirements apply to your product depends on its class, intended use, place of manufacture and registration route, and should be confirmed against the current official text for each individual case.
Back to the Regulation Library
